文献速递妇产影像US

基于多普勒的预测模型用于预测低危妊娠滋养细胞肿瘤伴子宫肌层浸润患者对甲氨蝶呤耐药:147例前瞻性研究

Doppler-based predictive model for methotrexate resistance in low-risk gestational trophoblastic neoplasia with myometrial invasion: prospective study of 147 patients.
PubMed 文献 · Ultrasound Obstet Gynecol · 2021-01-01

该前瞻性研究纳入2012年9月至2018年8月浙江大学医学院附属妇产科医院147例接受甲氨蝶呤一线治疗的低危妊娠滋养细胞肿瘤患者,利用多普勒超声评估血管化特征并建立甲氨蝶呤耐药预测模型。模型由子宫动脉时间平均平均流速和FIGO评分构成,在训练集交叉验证准确率74.4%,内部验证准确率72.7%,可将患者分为耐药低、中、高概率三层。

要点

  • 低危GTN伴肌层浸润者子宫肌层见血管丰富区,子宫动脉流速高、阻力低。
  • 预测模型公式为 y = -2.95332 + 0.41696 × FIGO评分 + 0.03551 × UtA-TAmean。
  • 模型AUC 0.757,最佳截断值0.50622时敏感度45.2%、特异度96.6%。

核心结论

  • 基于多普勒的预测模型结合肿瘤血管性无创标志物与FIGO评分系统,可区分低危GTN伴肌层浸润患者发生甲氨蝶呤耐药的低概率与高概率,因此有潜力指导治疗选择。

研究设计与样本

  • 前瞻性临床研究,纳入2012年9月至2018年8月浙江大学医学院附属妇产科医院接受一线甲氨蝶呤治疗的低危GTN患者147例,其中训练集110例、测试集37例。
  • 主要终点为建立并内部验证甲氨蝶呤耐药预测模型,训练集采用逻辑回归分析临床特征与甲氨蝶呤治疗前多普勒血流动力学参数。
  • 模型在训练数据集采用留一交叉验证评估预测性能,并在独立样本测试数据集进行内部验证。

关键影像表现/征象

  • 训练集中伴肌层浸润者占81.8%(90/110),其子宫肌层见血管丰富区,子宫动脉流速高、阻抗比低,与无肌层浸润者(18.2%,20/110)相比。

诊断标准与关键数值

  • 多因素逻辑回归显示子宫动脉时间平均平均流速(UtA-TAmean)与FIGO评分是甲氨蝶呤耐药的独立预测因素(P=0.009和P=0.043)。
  • 基于90例肌层浸润病例建立的多普勒预测模型为 y = -2.95332 + 0.41696 × FIGO评分 + 0.03551 × UtA-TAmean。
  • 模型曲线下面积为0.757(95%CI 0.653-0.862),最佳截断值0.50622,敏感度45.2%、特异度96.6%。
  • 模型以阈值-1.59544和0.10046将低危GTN患者分为甲氨蝶呤耐药低概率(<10%)、中概率(10-90%)和高概率(>90%)三层。
  • 模型交叉验证准确率74.4%(95%CI 64.5-82.3%),内部验证准确率72.7%(95%CI 55.8-84.9%)。

临床应用与阅片要点

  • 对低危GTN伴肌层浸润患者,可于甲氨蝶呤治疗前测量子宫动脉时间平均平均流速并结合FIGO评分计算模型预测值,辅助识别耐药高概率者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This prospective clinical study aimed to evaluate the vascularization characteristics of low-risk gestational trophoblastic neoplasia (GTN) using Doppler imaging and to develop a predictive model for resistance to methotrexate (MTX).

METHODS: Patients with low-risk GTN receiving primary MTX treatment were enrolled from the Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China, from September 2012 to August 2018. The primary endpoint was to develop and internally validate a predictive model for resistance to MTX therapy in these patients. In the training set, clinical features and Doppler hemodynamic parameters before MTX therapy were analyzed using logistic regression to identify independent predictors of MTX resistance, which were integrated into the model. The predictive performance of the model was evaluated by leave-one-out cross-validation in the training dataset and internal validation in an independent-sample test dataset.

RESULTS: The entire imaging protocol was completed by 147 eligible patients, of which 110 comprised the training set and 37 the test set. In the training set, cases with myometrial invasion (81.8%; 90/110) showed vascular-enriched areas in the myometrium and high velocity and low impedance ratios of the uterine artery (UtA) compared to cases without myometrial invasion (18.2%; 20/110). On multivariate logistic regression analysis, time-averaged mean velocity in UtA (UtA-TAmean) and the International Federation of Gynecology and Obstetrics (FIGO) score were identified as independent predictors (P = 0.009 and P = 0.043, respectively) of MTX resistance. The Doppler-based predictive model, developed based on the 90 cases with myometrial invasion, was y = -2.95332 + 0.41696 × FIGO score + 0.03551 × UtA-TAmean. The model showed an area under the curve of 0.757 (95% CI, 0.653-0.862) and the optimal cut-off value was 0.50622, which had 45.2% sensitivity and 96.6% specificity. The model stratified patients with low-risk GTN into low (< 10%), intermediate (10-90%) and high (> 90%) probability of MTX resistance, based on the threshold values of -1.59544 and 0.10046. The model had an accuracy of 74.4% (95% CI, 64.5-82.3%) in the cross-validation and 72.7% (95% CI, 55.8-84.9%) in the internal validation.

CONCLUSIONS: The Doppler-based predictive model, combining a non-invasive marker of tumor vascularity with the FIGO scoring system, can differentiate cases with low from those with high probability of developing MTX resistance and therefore has the potential to guide treatment options in patients with low-risk GTN and myometrial invasion. © 2020 Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Qin J, Zhang S, Poon L, et al. Doppler-based predictive model for methotrexate resistance in low-risk gestational trophoblastic neoplasia with myometrial invasion: prospective study of 147 patients. Ultrasound Obstet Gynecol. 2021. PMID: 32385928. doi:10.1002/uog.22069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。